中文名稱:LP-533401 | 英文名稱:LP-533401 |
CAS:945976-43-2 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 945976-43-2 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號 | 型號 |
LP-533401 | 1mg 5mg 10mg 25mg | 945976-43-2 | EY-Y0164356 |
Cas No.945976-43-2
別名 N/A
化學名 N/A
分子式 C27H22F4N4O3
分子量 526.5
溶解度 DMF: 10 mg/ml,DMF:PBS(pH7.2) (1:2): 0.33 mg/ml,DMSO: 5 mg/ml
儲存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
LP-533401 is a Tryptophan hydroxylase 1 inhibitor that regulates serotonin production in the gut.
LP-533401 completely inhibits serotonin production in Tph1–expressing cells (RBL2H3 cells) at a dose of 1 μM[1].
Oral administration once daily for up to 6 weeks of this small molecule prevents the development of and fully rescues, in a dose-dependent manner, osteoporosis in ovariectomized rodents because of an isolated increase in bone formation. Pharmacokinetic studies in rodents show that LP-533401 level in the brain is negligible following oral administration, indicating that it is virtually unable to cross the blood-brain barrier[1]. Mice treated repeatedly with LP-533401 (30–250 mg/kg per day) exhibit marked 5-HT content reductions in the gut, lungs, and blood, but not in the brain. After a single LP533401 dose (250 mg/kg), lung and gut 5-HT contents decrease by 50%, whereas blood 5-HT levels remain unchanged, suggesting gut and lung 5-HT synthesis[2]. Adult, healthy mice treated with the Tph-1 inhibitor LP-533401 show 30% decrease in circulating serotonin levels, with a consequent 30% increase in osteoblast numbers. Administration of LP533401 to mice injected with EL4 cells inhibits the decrement in osteoblast numbers and trabecular bone volume, prolongs survial, and decreases leukemic infiltration[3].
References:
[1]. Yadav, V.K., et al. Inhibition of gut-derived serotonin synthesis: A potential bone anabolic treatment. Nat. Med. 16(3), 308-312 (2010).
[2]. Abid S, et al. Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2012 Sep 15;303(6):L500-8.
[3]. Krevvata M, et al. Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood. 2014 Oct 30;124(18):2834-46.
成立日期 | 2014-06-05 (11年) | 注冊資本 | 100 |
員工人數(shù) | 50-100人 | 年營業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 生化試劑,抗體,細胞培養(yǎng),分子生物學,免疫安全 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP3年
|
吉奧藍圖(廣東)生命科學技術(shù)中心
|
2024-12-31 | |
詢價 |
VIP7年
|
臺州市科瑞生物技術(shù)有限公司
|
2024-12-11 | |
詢價 |
廣州市格瑞林生物科技有限公司
|
2025-01-07 | ||
¥19800 |
VIP3年
|
TargetMol中國(陶術(shù)生物)
|
2024-12-12 |